Abstract
This study estimates mean 2017 total and out-of-pocket costs for infliximab and its biosimilar infliximab-dyyb under Medicare Part D.
Publication types
-
Research Support, N.I.H., Extramural
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Antirheumatic Agents / economics*
-
Biosimilar Pharmaceuticals / economics*
-
Cost Sharing*
-
Financing, Personal / statistics & numerical data*
-
Infliximab / economics*
-
Insurance Coverage
-
Medicare Part D
-
Prescription Fees
-
United States
Substances
-
Antirheumatic Agents
-
Biosimilar Pharmaceuticals
-
Infliximab